Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs Manhattan Associates Inc (MANH) Price & Performance

BridgeBio Pharma IncTrade
Manhattan Associates IncTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs Manhattan Associates Inc — how do they compare? BridgeBio Pharma Inc trades at $83.61 (market cap $16.36B), while Manhattan Associates Inc trades at $190.4 (market cap $11.38B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Manhattan Associates Inc nearer its low. Which is the better fit depends on your goals.

BBIOMANH
Market Cap
$16.36B$11.38B
Sector
HealthTechnology
52-Week High
$90.17$220.19
52-Week Low
$47.29$120.88
Enterprise Value
$18.14B$11.25B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.

The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.

Manhattan Associates Inc

MANH trades at $189.98, down 2.92% on the day, but maintains a bullish technical outlook with strong moving average signals and a golden cross formation. The company reported Q2 2026 EPS of $1.39, beating estimates, with cloud revenue growth driving performance. However, high valuation ratios like a P/E of 55.93 and P/B of 72.26 suggest premium pricing. Recent news highlights an ongoing legal investigation into fiduciary duties by Rosen Law Firm, adding a layer of scrutiny.

The stock's upside is supported by analyst consensus with a $210.33 price target and 80% buy ratings, but risks include elevated valuations, potential legal overhangs, and projected net cash flow turning negative in 2026. Investors should weigh robust profitability metrics against these headwinds for balanced decision-making.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About Manhattan Associates Inc

Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.

Read more on MANH